1Sadler J E, Mannueci P M, Berntorp E, et al. Impact,Diagnosis and Treatment of yon Willebrand Disease.Thromb Haemost, 2000, 84:160-174.
2Ginsburg D, Handin R I, Bonthron D T, et al. Human yon Willebrand factor (vWF) : Isolation of complementary DNA (eDNA) clones and chromosomal localization. Science, 1985, 228;1401-1406.
3Ginsburg D, Bowie E J W. Molecular Genetics of von Willebrand Disease. Blood, 1992, 79:2507-2519.
4Furlan M, Robles R, Lammle B, et al. Partial purification and characterization of a protease from human plasma cleaving yon Willebrand factor to fragments produced by in vivo proteolysis. Blood, 1996, 87:4223-4234.
5Borchiellini A, Fijnvandraat K, Cate J W, et al. Quantitative analysis of yon Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood, 1996, 88:2951-2958.
6Haley E, Babar N, Ritter C, et al. Effect of ABO blood group on the collegen-bindin assay for yon Willebrand factor. AmJ Hemotol, 2002, 71:229-233.
7Sadler J E. A revised classification of von Willebrand disease. Thromb Haemost, 1994, 71:520-525.
8Sadler J E, Gralnick H R. Commentary: a new classification of yon Willebrand disease. Blood, 1994, 84 : 676-679.
9Nichols W C, Ginsburg D. von Willebrand disease.Medicine, 1997, 76:1-20.
10Dean J A, Blanchette V S, Carcao M D, et al. von Willebrand Disease in a Pediatric-based Population-Comparison of Type 1 Diagnostic Criteria and Use of the PFA-100 and a yon Willebrand Factor/Collagen-binding Assay. Thromb Haemost, 2000, 84:401-409.
